Inhibition of respiratory syncytial virus of subgroups A and B using deoxyribozyme DZ1133 in mice

Virus Research

Volumn 130, Issue 1-2, 2007, Pages 241-248

  Zhou, Juan ^a   Yang, Xi Qiang ^a   Xie, Yuan Yuan ^a   Zhao, Xiao Dong ^a   Jiang, Li Ping ^a   Wang, Li Jia ^a   Cui, Yu Xia ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Antiviral; Deoxyribozyme; Mice; Respiratory syncytial virus

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; AS 1133; DEOXYRIBOZYME; DZ 1133; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; NUCLEOCAPSID PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; IMMUNE RESPONSE; LEUKOCYTE COUNT; LUNG LAVAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RNA SEQUENCE; VIRUS INFECTION; VIRUS INHIBITION; VIRUS PLAQUE; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTIVIRAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; DNA, CATALYTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INFLAMMATION; LEUKOCYTE COUNT; LUNG; MICE; MICE, INBRED BALB C; PLAQUE ASSAY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RNA, MESSENGER; RNA, VIRAL;

MUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 35748941347     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2007.06.017     Document Type: Article

References (52)

1. Achenbach J.C., Chiuman W., Cruz R.P.G., and Li Y. DNAzymes: from creation in vitro to application in vivo. Curr. Pharm. Biotechnol. 5 (2004) 321-336
2. Ali S., Leonard S.A., Kukoly C.A., Metzger W.J., Wooles W.R., McGinty J.F., Tanaka M., Sandrasagra A., and Nyce J.W. Absorption, distribution, metabolism, and excretion of a respirable antisense oligonucleotide for asthma. Am. J. Respir. Crit. Care Med. 163 (2001) 989-993
3. Barik S., and Bitko V. Prospects of RNA interference therapy in respiratory viral diseases: update. Expert Opin. Biol. Ther. 6 (2006) 1151-1160
4. Barnard D.L., Sidwell R.W., Xiao W., Player M.R., Adah S.A., and Tirrence P.F. 2-5A-DNA conjugate inhibition of respiratory syncytial virus replication effects of oligonucleotide structure modifications and RNA target site selection. Antivir. Res. 41 (1999) 119-134
5. Beigelman L., McSwiggen J.A., Draper K.G., Gonzalez C., Jensen K., Karpeisky A.M., Modak A.S., Matulic-Adamic J., DiRenzo A.B., and Haeberli P. Chemical modification of hammerhead ribozymes: catalytic activity and nuclease resistance. J. Biol. Chem. 270 (1995) 25702-25708
6. Bitko V., Musiyenko A., Shulyayeva O., and Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 11 (2005) 50-55
7. Black C.P. Systematic review of the biology and medical management of respiratory syncytial virus infection. Respir. Care 48 (2003) 209-233
8. Blanco J.C., Boukhvalova M.S., Hemming P., Ottolini M.G., and Prince G.A. Prospects of antiviral and anti-inflammatory therapy for respiratory syncytial virus infection. Expert Rev. Anti Infect. Ther. 3 (2005) 945-955
9. Bitko V., and Barik S. Intranasal antisense therapy: preclinical models with a clinical future?. Curr. Opin. Mol. Ther. 9 (2007) 119-125
10. Braciale T.J. Respiratory syncytial virus and T cells: interplay between the virus and the host adaptive immune system. Proc. Am. Thorac. Soc. 2 (2005) 141-146
11. Breaker R.R. Making catalytic DNAs. Science 290 (2000) 2095-2096
12. Chakraborti S., and Banerjea A.C. Inhibition of HIV-1 gene expression by novel DNA enzymes targeted to cleave HIV-1 TAR RNA potential effectiveness against all HIV-1 isolates. Mol. Ther. 7 (2003) 817-826
13. Chen M.D., Vazquez M., Buonocore L., and Kahn J.S. Conservation of the respiratory syncytial virus SH gene. J. Infect. Dis. 182 (2000) 1228-1233
14. Cimolai N., Taylor G.P., Mah D., and Morrison B.J. Definition and application of a histopathological scheme for an animal model of acute Mycoplasma pneumoniae pulmonary infection. Microbial. Immunol. 36 (1992) 465-478
15. Cirion N.M., Li G., Xiao W., Torrence P.F., and Silverman R.H. Targeting RNA decay with 2′5′oligoadenylate-antisense in respiratory syncytial virus-infected cells. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 1937-1942
16. Collins P.L., Hill M.G., and Johnson P.R. The two open reading frames of the 22 K mRNA of human respiratory syncytial virus: sequence comparison of antigenic subgroups A and B and expression in vitro. J. Gen. Virol. 71 Pt. 12 (1990) 3015-3020
17. Collins P.L., Olmsted R.A., and Johnson P.R. The small hydrophobic protein of human respiratory syncytial virus: comparison between antigenic subgroups A and B. J. Gen. Virol. 71 Pt. 7 (1990) 1571-1576
18. Cramer H. Antisense approaches for inhibiting respiratory syncytial virus. Expert Opin. Biol. Ther. 5 (2005) 207-220
19. Dass C.R. Deoxyribozymes: cleaving a path to clinical trials. Trends Pharm. Sci. 25 (2004) 395-397
20. Durbin J.E., Johnson T.R., Durbin R.K., Mertz S.E., Morotti R.A., Peebles R.S., and Graham B.S. The role of IFN in respiratory syncytial virus pathogenesis. J. Immunol. 168 (2002) 2944-2952
21. Grosfeld H., Hill M.G., and Collins P.L. RNA replication by respiratory syncytial virus (RSV) is directed by the N, P, and L proteins; transcription also occurs under these conditions but requires RSV superinfection for efficient synthesis of full length mRNA. J. Virol. 69 (1995) 5677-5686
22. Guerguerian A.M., Gauthier M., Lebel M.H., Farrell C.A., and Lacroix J. Ribavirin in ventilated respiratory syncytial virus bronchiolitis: arandomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 160 (1999) 829-834
23. Guney C., Kubar A., Yapar M., Besirbellioglu A.B., and Doganci L. An outbreak of respiratory infection due to respiratory syncytial virus subgroup B in Ankara. Turkey Jpn. J. Infect. Dis. 57 (2004) 178-180
24. Holt P.C., and S1y P.D. Interactions between RSV infection, asthma and atopy: unraveling the complexities. J. Exp. Med. 196 (2002) 1271-1275
25. Isaka Y., Nakamura H., Mizui M., Takabatake Y., Horio M., Kawach H., Shimizu F., Imai E., and Hori M. DNAzyme for TGF-β suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int. 66 (2004) 586-590
26. Jennifer L., and McKimm-Breschkin. A simplified plaque assay for respiratory syncytial virus-direct visualization of plaques without immunostaining. J. Virol. Methods 120 (2004) 113-117
27. Kalina W.V., and Gershwin L.J. Progress in defining the role of RSV in allergy and asthma: from clinical observations to animal models. Clin. Dev. Immunol. 11 (2004) 113-119
28. Kuroiwa Y., Nagai K., Okita L., and Tsutsumi H. Genetic variability and molecular epidemiology of respiratory syncytial virus subgroup a strains in Japan determined by heteroduplex mobility assay. J. Clin. Microbiol. 42 (2004) 2048-2053
29. Leaman D.W., Longano F.J., Okicki J.R., Soike K.F., Torrence P.F., Silverman R.H., and Cramer H. Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-5A-antisense. Virology 292 (2002) 70-77
30. Liu C., Cheng R., Sun L.Q., and Tien P. Suppression of platelet-type 12-lipoxygenase activity in human erythroleukemia cells by an RNA-cleaving DNAzyme. Biochem. Biophys. Res. Commun. 284 (2001) 1077-1082
31. Long C.E., Voter K.Z., Barker W.H., and Hall C.B. Long term follow-up of children hospitalized with respiratory syncytial virus lower respiratory tract infection and randomly treated with ribavirin or placebo. Pediatr. Infect. Dis. J. 16 (1997) 1023-1028
32. Lowe H.C., Fahmy R.G., Kavurma M.M., Baker A., Chesterman C.N., and Khachigian L.M. Catalytic oligodeoxynucleotides define a key regulatory role for early growth response factor-1 in the porcine model of coronary in-stent restenosis. Circ. Res. 89 (2001) 670-677
33. McNamara P.S., and Smyth R.L. The pathogenesis of respiratory syncytial virus disease in childhood. Br. Med. Bull. 61 (2002) 13-28
34. Openshaw P.J. Antiviral immune responses and lung inflammation after respiratory syncytial virus infection. Proc. Am. Thorac. Soc. 2 (2005) 121-125
35. Openshaw P.J., Dean G.S., and Culley F.J. Links between respiratory syncytial virus bronchiolitis and childhood asthma: clinical and research approaches. Pediatr. Infect. Dis. J. 22 Suppl. 2 (2003) S58-S65
36. Peter B.C.F., Panteleyev FA.A., and Christiano A.M. Recapitulation of the hairless mouse phenotype using catalytic oligonucleotides: implications for permanent hair removal. Exp. Dermatol. 13 (2004) 155-162
37. Phillips M.I., and Zhang Y.C. Basic principles of using antisense oligonucleotides in vivo. Methods Enzymol. 313 (2000) 46-56
38. Player M.R., B arnard D.L., and Torrence P.F. Potent inhibition of respiratory syncytial virus replication using a 2-5A-antisense chimera targeted to signals within the virus genomic RNA. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 8874-8879
39. Rutigliano J.A., and Graham B.S. Prolonged production of TNF-alpha exacerbates illness during respiratory syncytial virus infection. J. Immunol. 173 (2004) 3408-3417
40. Santoro S.W., and Joyce G.F. A general porpose RNA-cleaving DNA enzyme. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 4262-4266
41. Schubert S., and Kurreck J. Ribozyme- and deoxyribozyme-strategies for medical applications. Curr. Drug Target 5 (2004) 667-681
42. Sullender W.M. Respiratory syncytial virus genetic and antigenic diversity. Clin. Microbiol. Rev. 13 (2000) 1-15
43. Sun L.Q., Cairns M.J., Saravolac E.G., Barker A., and Gerlach W.L. Catalytic nucleic acids: from lab to applications. Pharmacol. Rev. 52 (2000) 325-347
44. Takahashia H., Hamazakia H., Habua Y., Hayashi M., Abe T., Miyano-Kurosaki N., and Takaku H. A new modified DNA enzyme that targets infuenza virus A mRNA inhibits viral infection in cultured cells. FEBS Lett. 560 (2004) 69-74
45. Toyoda T., Imamura Y., Takaku H., Kashiwagi T., Hara K., Iwahashi J., Ohtsu Y., Tsumura N., Kato H., and Hamada N. Inhibition of influenza virus replication in cultured cells by RNA-cleaving DNA enzyme. FEBS Lett. 481 (2000) 113-116
46. Trepanier J., Tanner J.E., Momparler R.L., Le O.N., Alvarez F., and Alfieri C. Cleavage of intracellular hepatitis C RNA in the virus core protein coding region by deoxyribozymes. J. Viral Hepat. 13 (2006) 131-138
47. Wang D.Y., Lai B.H., Feldman A.R., and Sen D. A general approach for the use of oligonucleotide effectors to regulate the catalysis of RNA-cleaving ribozymes and DNAzymes. Nucleic Acids Res. 30 (2002) 1735-1742
48. Wang S.Z., Bao Y.X., Rosenberger C.L., Tesfaigzi Y., Stark J.M., and Harrod K.S. IL-12p40 and IL-18 modulate inflammatory and immune responses to respiratory syncytial virus infection. J. Immunol. 173 (2004) 4040-4049
49. Xie Y.Y., Zhao X.D., Jiang L.P., Liu H.L., Wang L.J., Fang P., Shen K.L., Xie Z.D., Wu Y.P., and Yang X.Q. Inhibition of respiratory syncytial virus in cultured cells by nucleocapsid gene targeted deoxyribozyme (DNAzyme). Antivir. Res. 71 (2006) 31-41
50. Zaborowska Z., Fürste J.P., Erdmann V.A., and Kurreck J. Sequence requirements in the catalytic core of the "10-23" DNA enzyme. J. Biol. Chem. 277 (2002) 40617-40622
51. Zhang G., Dass C.R., Sumithran E., Girolamo N.D., Sun L.Q., and Khachigian L.M. Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. J. Natl. Cancer Inst. 96 (2004) 683-696
52. Zhao C.A., Zhao X.D., Yu H.G., Wu Y.P., and Yang X.Q. Inhibition of respiratory syncytial virus replication in cultured cells by RNA-cleaving DNAzyme. Zhonghua Er Ke Za Zhi. 41 (2003) 594-597